In the coming year, we propose to test the efficacy of combination therapy of SPRM (ulipristal acetate) and selective COX-2 inhibitor (Celecoxib) for prevention of Brca1 deficient mammary tumorigenesis in a mouse model.
|Effective start/end date||10/1/20 → 9/30/22|
- Breast Cancer Research Foundation (BCRF-20-087)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.